Sangamo BioSciences | SGMO - Assets


Sangamo BioSciences reported $97.56M in Assets for its fiscal quarter ending in June of 2025.





Assets Change Date
Alaunos Therapeutics USD 1.88M 1.08M Mar/2026
Alnylam Pharmaceuticals USD 5.56B 429.22M Jun/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Amgen USD 95.64B 3.14B Jun/2026
Bayer EUR 107.29B 659M Jun/2026
BioCryst Pharmaceuticals USD 557.85M 92.8M Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
BioMarin Pharmaceutical USD 11.72B 3.13B Jun/2026
Cipla INR 424.96B 23.32B Mar/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 145.86M 10.71M Mar/2026
CSL USD 37.9B 1.5B Dec/2025
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Grifols EUR 23.15B 142.7M Dec/2025
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Merck USD 129.8B 1.12B Jun/2026
Novartis USD 122.03B 3.5B Jun/2026
Omeros USD 200.57M 34.59M Jun/2025
Pfizer USD 201.13B 6.49B Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 129.06B 1.04B Jun/2026
Sarepta Therapeutics USD 3.19B 9.58M Jun/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.26B 32M Jun/2026
Vertex Pharmaceuticals USD 27.42B 938.9M Jun/2026